36 unchanged sentences
On June 11, 2020, FibroGen and Astellas appealed the Patents Court’s judgment on the invalidity of the ’823 EP Patent (UK), the ’301 EP Patent (UK), the ’333 EP Patent (UK), the ’153 EP Patent (UK), and the ’155 EP Patent (UK) in the Court of Appeal (Civil Division).
−Removed: On June 8, 2021 - June 10, 2021, the United Kingdom Court of Appeal held a three-day hearing for the appeal.
+Added: On June 8, 2021 - June
+Added: Akebia Therapeutics, Inc.
+Added: | Form 10-Q | Page 36
+Added: 10, 2021, the United Kingdom Court of Appeal held a three-day hearing for the appeal.
On August 24, 2021, the Court of Appeal issued a judgment, which reversed the Patents Court’s judgment on the invalidity of the ’823 EP Patent (UK) and maintained certain claims of the ’823 EP Patent (UK) and the ’301 EP Patent (UK) in amended form, and which affirmed the Patents Court’s judgment on the invalidity of the ’333 EP Patent (UK), the ’155 EP Patent (UK), and the ’153 EP Patent (UK).
2 unchanged sentences
We do not expect the UK Court of Appeal’s judgment to have any effect on our commercialization of vadadustat in the UK because the patents expired in December 2022.
−Removed: Akebia Therapeutics, Inc.
−Removed: | Form 10-Q | Page 39
Legal Proceedings Relating to Auryxia
45 unchanged sentences
Briefing on defendants’ motion to dismiss the amended consolidated complaint was completed on April 5, 2023.
−Removed: Oral argument is currently scheduled to be held on October 18, 2023.
+Added: Oral argument is currently scheduled to be held on January 12, 2024.
+Added: Akebia Therapeutics, Inc.
+Added: | Form 10-Q | Page 37
We deny any allegations of wrongdoing and intend to continue vigorously defending against the one active stockholder lawsuit described in this Legal Proceedings section, the Consolidated State Action.
2 unchanged sentences
A resolution of the Consolidated State Action in a manner adverse to us, however, could have a material effect on our financial position and results of operations in the period in which the action is resolved.
−Removed: Akebia Therapeutics, Inc.
−Removed: | Form 10-Q | Page 40
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.